Artal Group S.A. Autolus Therapeutics PLC Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$8.13 - $12.79 $2.32 Million - $3.65 Million	-285,000 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$11.64 - $16.3 $1.34 Million - $1.87 Million	-115,000 Reduced 28.75%	285,000 $3.32 Million
Q2 2020 Aug 14, 2020	SELL	$5.38 - $16.14 $538,000 - $1.61 Million	-100,000 Reduced 20.0%	400,000 $6.41 Million
Q2 2019 Aug 09, 2019	BUY	$15.1 - $31.25 $755,000 - $1.56 Million	50,000 Added 11.11%	500,000 $8.05 Million
Q1 2019 May 10, 2019	SELL	$24.38 - $34.71 $609,500 - $867,750	-25,000 Reduced 5.26%	450,000 $14.2 Million

Q4 2018 Feb 11, 2019	SELL	$24.21 - $48.01 $605,250 - $1.2 Million	-25,000 Reduced 5.0%	475,000 $15.6 Million
Q3 2018 Nov 09, 2018	SELL	$20.86 - $33.33 $521,500 - $833,250	-25,000 Reduced 4.76%	500,000 $15.3 Million
Q2 2018 Aug 10, 2018	BUY	$25.0 - $27.75 $13.1 Million - $14.6 Million	525,000 New	525,000 $14.1 Million

123

168M

411K

67.6K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $307M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.